APP and Alzheimer disease: In addition, 33i treatment reduced the neuroinflammation in the hippocampus of APP/PS1 mice supporting previously data published in a mouse model of accelerated senescence (Diaz-Perdigon et al. 2020) and the potential of SIRT2 as a pharmacological target for the treatment of AD.